Bruker Corp 8-K, filed Nov 5, 2026
Bruker Corp (BRKR)
About this 8-K
Bruker Corp filed this 8-K on November 5, 2026.
Bruker Corporation completed a reportable segment reorganization effective July 1, 2026, creating BSI BIOS and BSI Microbiology and Infection Diagnostics while retaining BSI NANO and BEST. Recast historical segment data has no impact on consolidated results, financial position or cash flows. AI summary
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
||
|
|
|
(State or other jurisdiction of |
(Commission |
(I.R.S. Employer |
incorporation) |
File number) |
Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
|
|
|||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
As previously announced, effective July 1, 2026 (the “Effective Date”), Bruker Corporation (the “Company”) completed a reorganization of its reportable segments to streamline its organizational structure and further facilitate decision making, accountability, customer focus, and innovation. Prior to the Effective Date, the Company had the following four reportable segments: (i) Bruker Scientific Instruments (“BSI”) BioSpin, (ii) BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), (iii) BSI NANO, and (iv) Bruker Energy & Supercon Technologies (“BEST”).
As a result of this reorganization, as of the Effective Date, the Company’s reportable segments consist of the following four reportable segments:
For information purposes and to provide investors with historical information on a basis consistent with its new reporting structure, the Company has provided recast reportable segment information that conforms to the new reporting structure. This reportable operating segment realignment did not impact the Company’s historical consolidated results of operations, financial position or cash flows.
Attached as Exhibit 99.1 and incorporated by reference in this Item 8.01 are schedules containing recast reportable segment information for the years ended December 31, 2025 and 2024, the three months ended March 31, 2025 and 2026, the three and six months ended June 30, 2025 and 2026, and the three and nine months ended September 30, 2025. The recast information has been derived from, and should be read in conjunction with, the Company's previously filed Annual Reports on Form 10-K for the years ended December 31, 2025 and 2024, and Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and 2026, June 30, 2025 and 2026, and September 30, 2025, in which the corresponding financial information was originally reported.
As noted above, the segment changes and supplemental disclosures discussed above have no impact on the Company’s historical consolidated results of operations, financial position or cash flows. The recast financial information contained in Exhibit 99.1 does not represent a restatement of the Company’s previously issued financial statements.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) |
Exhibits. |
||
|
|
|
|
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BRUKER CORPORATION |
|
|
|
|
Date: November 5, 2026 |
By: |
/s/ THOMAS M. BURES |
|
|
Thomas M. Bures |
|
|
Chief Accounting Officer |
Exhibit 99.1
|
As Reported |
|
|
As Recast |
|
||||||||||||||||||||||||||||||||
|
Bruker Scientific Instruments ("BSI") BioSpin |
|
BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection ("BSI CALID") |
|
BSI NANO |
|
Bruker Energy & Supercon Technologies ("BEST") |
|
Corporate |
|
Total |
|
|
BSI Biosystems ("BIOS") |
|
BSI Microbiology and Infection Diagnostics ("BMID") |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
||||||||||||
Three months ended March 31, 2026 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
197.5 |
|
$ |
316.3 |
|
$ |
246.0 |
|
$ |
63.6 |
|
|
— |
|
$ |
823.4 |
|
|
$ |
381.5 |
|
$ |
132.3 |
|
$ |
246.0 |
|
$ |
63.6 |
|
|
— |
|
$ |
823.4 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
3.2 |
|
|
— |
|
|
3.2 |
|
|
|
— |
|
|
— |
|
|
— |
|
$ |
3.2 |
|
|
— |
|
|
3.2 |
|
Total segment revenue |
$ |
197.5 |
|
$ |
316.3 |
|
$ |
246.0 |
|
$ |
66.8 |
|
|
— |
|
$ |
826.6 |
|
|
$ |
381.5 |
|
$ |
132.3 |
|
$ |
246.0 |
|
$ |
66.8 |
|
|
— |
|
$ |
826.6 |
|
Gross profit |
$ |
88.9 |
|
$ |
167.7 |
|
$ |
109.1 |
|
$ |
14.1 |
|
|
— |
|
$ |
379.8 |
|
|
$ |
178.7 |
|
$ |
77.9 |
|
$ |
109.1 |
|
$ |
14.1 |
|
|
— |
|
$ |
379.8 |
|
Gross profit margin |
|
45.0 |
% |
|
53.0 |
% |
|
44.3 |
% |
|
21.1 |
% |
|
— |
|
|
46.1 |
% |
|
|
46.8 |
% |
|
58.9 |
% |
|
44.3 |
% |
|
21.1 |
% |
|
— |
|
|
46.1 |
% |
Operating income |
$ |
16.0 |
|
$ |
40.7 |
|
$ |
(21.8 |
) |
$ |
7.5 |
|
$ |
(32.2 |
) |
$ |
10.2 |
|
|
$ |
27.4 |
|
$ |
29.3 |
|
$ |
(21.8 |
) |
$ |
7.5 |
|
$ |
(32.2 |
) |
$ |
10.2 |
|
Operating margin |
|
8.1 |
% |
|
12.9 |
% |
|
(8.9 |
)% |
|
11.2 |
% |
|
— |
|
|
1.2 |
% |
|
|
7.2 |
% |
|
22.1 |
% |
|
(8.9 |
)% |
|
11.2 |
% |
|
— |
|
|
1.2 |
% |
|
As Reported |
|
|
As Recast |
|
||||||||||||||||||||||||||||||||
|
BSI BioSpin |
|
BSI CALID |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
|
BSI BIOS |
|
BSI BMID |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
||||||||||||
Three months ended June 30, 2026 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
195.7 |
|
$ |
310.3 |
|
$ |
261.3 |
|
$ |
71.2 |
|
|
— |
|
$ |
838.5 |
|
|
$ |
376.1 |
|
$ |
129.9 |
|
$ |
261.3 |
|
$ |
71.2 |
|
|
— |
|
$ |
838.5 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
3.0 |
|
|
— |
|
|
3.0 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
3.0 |
|
|
— |
|
|
3.0 |
|
Total segment revenue |
$ |
195.7 |
|
$ |
310.3 |
|
$ |
261.3 |
|
$ |
74.2 |
|
|
— |
|
$ |
841.5 |
|
|
$ |
376.1 |
|
$ |
129.9 |
|
$ |
261.3 |
|
$ |
74.2 |
|
|
— |
|
$ |
841.5 |
|
Gross profit |
$ |
98.8 |
|
$ |
172.6 |
|
$ |
131.4 |
|
$ |
13.2 |
|
|
— |
|
$ |
416.0 |
|
|
$ |
194.8 |
|
$ |
76.6 |
|
$ |
131.4 |
|
$ |
13.2 |
|
|
— |
|
$ |
416.0 |
|
Gross profit margin |
|
50.5 |
% |
|
55.6 |
% |
|
50.3 |
% |
|
17.8 |
% |
|
— |
|
|
49.6 |
% |
|
|
51.8 |
% |
|
59.0 |
% |
|
50.3 |
% |
|
17.8 |
% |
|
— |
|
|
49.6 |
% |
Operating income |
$ |
(64.6 |
) |
$ |
48.3 |
|
$ |
(20.9 |
) |
$ |
7.5 |
|
$ |
(35.6 |
) |
$ |
(65.3 |
) |
|
$ |
(45.8 |
) |
$ |
29.5 |
|
$ |
(20.9 |
) |
$ |
7.5 |
|
$ |
(35.6 |
) |
$ |
(65.3 |
) |
Operating margin |
|
(33.0 |
)% |
|
15.6 |
% |
|
(8.0 |
)% |
|
10.1 |
% |
|
— |
|
|
(7.8 |
)% |
|
|
(12.2 |
)% |
|
22.7 |
% |
|
(8.0 |
)% |
|
10.1 |
% |
|
— |
|
|
(7.8 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Six months ended June 30, 2026 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
393.2 |
|
$ |
626.6 |
|
$ |
507.3 |
|
$ |
134.8 |
|
|
— |
|
$ |
1,661.9 |
|
|
$ |
757.6 |
|
$ |
262.2 |
|
$ |
507.3 |
|
$ |
134.8 |
|
|
— |
|
$ |
1,661.9 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
6.2 |
|
|
— |
|
|
6.2 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
6.2 |
|
|
— |
|
|
6.2 |
|
Total segment revenue |
$ |
393.2 |
|
$ |
626.6 |
|
$ |
507.3 |
|
$ |
141.0 |
|
|
— |
|
$ |
1,668.1 |
|
|
$ |
757.6 |
|
$ |
262.2 |
|
$ |
507.3 |
|
$ |
141.0 |
|
|
— |
|
$ |
1,668.1 |
|
Gross profit |
$ |
187.6 |
|
$ |
340.3 |
|
$ |
240.5 |
|
$ |
27.4 |
|
|
— |
|
$ |
795.8 |
|
|
$ |
373.4 |
|
$ |
154.5 |
|
$ |
240.5 |
|
$ |
27.4 |
|
|
— |
|
$ |
795.8 |
|
Gross profit margin |
|
47.7 |
% |
|
54.3 |
% |
|
47.4 |
% |
|
19.4 |
% |
|
— |
|
|
47.9 |
% |
|
|
49.3 |
% |
|
58.9 |
% |
|
47.4 |
% |
|
19.4 |
% |
|
— |
|
|
47.9 |
% |
Operating income |
$ |
(48.6 |
) |
$ |
89.0 |
|
$ |
(42.7 |
) |
$ |
15.0 |
|
$ |
(67.8 |
) |
$ |
(55.1 |
) |
|
$ |
(18.4 |
) |
$ |
58.8 |
|
$ |
(42.7 |
) |
$ |
15.0 |
|
$ |
(67.8 |
) |
$ |
(55.1 |
) |
Operating margin |
|
(12.4 |
)% |
|
14.2 |
% |
|
(8.4 |
)% |
|
10.6 |
% |
|
— |
|
|
(3.3 |
)% |
|
|
(2.4 |
)% |
|
22.4 |
% |
|
(8.4 |
)% |
|
10.6 |
% |
|
— |
|
|
(3.3 |
)% |
|
As Reported |
|
|
As Recast |
|
||||||||||||||||||||||||||||||||
|
BSI BioSpin |
|
BSI CALID |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
|
BSI BIOS |
|
BSI BMID |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
||||||||||||
Three months ended March 31, 2025 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
207.8 |
|
$ |
280.1 |
|
$ |
256.6 |
|
$ |
56.9 |
|
|
— |
|
$ |
801.4 |
|
|
$ |
368.9 |
|
$ |
119.0 |
|
$ |
256.6 |
|
$ |
56.9 |
|
|
— |
|
$ |
801.4 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
2.4 |
|
|
— |
|
|
2.4 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
2.4 |
|
|
— |
|
|
2.4 |
|
Total segment revenue |
$ |
207.8 |
|
$ |
280.1 |
|
$ |
256.6 |
|
$ |
59.3 |
|
|
— |
|
$ |
803.8 |
|
|
$ |
368.9 |
|
$ |
119.0 |
|
$ |
256.6 |
|
$ |
59.3 |
|
|
— |
|
$ |
803.8 |
|
Gross profit |
$ |
93.7 |
|
$ |
153.3 |
|
$ |
131.4 |
|
$ |
12.8 |
|
|
— |
|
$ |
391.2 |
|
|
$ |
178.9 |
|
$ |
68.1 |
|
$ |
131.4 |
|
$ |
12.8 |
|
|
— |
|
$ |
391.2 |
|
Gross profit margin |
|
45.1 |
% |
|
54.7 |
% |
|
51.2 |
% |
|
21.6 |
% |
|
— |
|
|
48.8 |
% |
|
|
48.5 |
% |
|
57.2 |
% |
|
51.2 |
% |
|
21.6 |
% |
|
— |
|
|
48.8 |
% |
Operating income |
$ |
23.7 |
|
$ |
40.2 |
|
$ |
(7.0 |
) |
$ |
6.9 |
|
$ |
(32.0 |
) |
$ |
31.8 |
|
|
$ |
40.5 |
|
$ |
23.4 |
|
$ |
(7.0 |
) |
$ |
6.9 |
|
$ |
(32.0 |
) |
$ |
31.8 |
|
Operating margin |
|
11.4 |
% |
|
14.4 |
% |
|
(2.7 |
)% |
|
11.6 |
% |
|
— |
|
|
4.0 |
% |
|
|
11.0 |
% |
|
19.7 |
% |
|
(2.7 |
)% |
|
11.6 |
% |
|
— |
|
|
4.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Three months ended June 30, 2025 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
195.3 |
|
$ |
285.8 |
|
$ |
252.1 |
|
$ |
64.2 |
|
|
— |
|
$ |
797.4 |
|
|
$ |
357.0 |
|
$ |
124.1 |
|
$ |
252.1 |
|
$ |
64.2 |
|
|
— |
|
$ |
797.4 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
2.1 |
|
|
— |
|
|
2.1 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
2.1 |
|
|
— |
|
|
2.1 |
|
Total segment revenue |
$ |
195.3 |
|
$ |
285.8 |
|
$ |
252.1 |
|
$ |
66.3 |
|
|
— |
|
$ |
799.5 |
|
|
$ |
357.0 |
|
$ |
124.1 |
|
$ |
252.1 |
|
$ |
66.3 |
|
|
— |
|
$ |
799.5 |
|
Gross profit |
$ |
83.4 |
|
$ |
145.3 |
|
$ |
115.9 |
|
$ |
13.3 |
|
|
— |
|
$ |
357.9 |
|
|
$ |
157.6 |
|
$ |
71.1 |
|
$ |
115.9 |
|
$ |
13.3 |
|
|
— |
|
$ |
357.9 |
|
Gross profit margin |
|
42.7 |
% |
|
50.8 |
% |
|
46.0 |
% |
|
20.1 |
% |
|
— |
|
|
44.9 |
% |
|
|
44.1 |
% |
|
57.3 |
% |
|
46.0 |
% |
|
20.1 |
% |
|
— |
|
|
44.9 |
% |
Operating income |
$ |
18.1 |
|
$ |
26.2 |
|
$ |
(13.4 |
) |
$ |
7.2 |
|
$ |
(26.2 |
) |
$ |
11.9 |
|
|
$ |
18.3 |
|
$ |
26.0 |
|
$ |
(13.4 |
) |
$ |
7.2 |
|
$ |
(26.2 |
) |
$ |
11.9 |
|
Operating margin |
|
9.3 |
% |
|
9.2 |
% |
|
(5.3 |
)% |
|
10.9 |
% |
|
— |
|
|
1.5 |
% |
|
|
5.1 |
% |
|
21.0 |
% |
|
(5.3 |
)% |
|
10.9 |
% |
|
— |
|
|
1.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Six months ended June 30, 2025 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
403.1 |
|
$ |
565.9 |
|
$ |
508.7 |
|
$ |
121.1 |
|
|
— |
|
$ |
1,598.8 |
|
|
$ |
725.9 |
|
$ |
243.1 |
|
$ |
508.7 |
|
$ |
121.1 |
|
|
— |
|
$ |
1,598.8 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
4.5 |
|
|
— |
|
|
4.5 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
4.5 |
|
|
— |
|
|
4.5 |
|
Total segment revenue |
$ |
403.1 |
|
$ |
565.9 |
|
$ |
508.7 |
|
$ |
125.6 |
|
|
— |
|
$ |
1,603.3 |
|
|
$ |
725.9 |
|
$ |
243.1 |
|
$ |
508.7 |
|
$ |
125.6 |
|
|
— |
|
$ |
1,603.3 |
|
Gross profit |
$ |
177.1 |
|
$ |
298.7 |
|
$ |
247.3 |
|
$ |
26.0 |
|
|
— |
|
$ |
749.1 |
|
|
$ |
336.6 |
|
$ |
139.2 |
|
$ |
247.3 |
|
$ |
26.0 |
|
|
— |
|
$ |
749.1 |
|
Gross profit margin |
|
43.9 |
% |
|
52.8 |
% |
|
48.6 |
% |
|
20.7 |
% |
|
— |
|
|
46.9 |
% |
|
|
46.4 |
% |
|
57.3 |
% |
|
48.6 |
% |
|
20.7 |
% |
|
— |
|
|
46.9 |
% |
Operating income |
$ |
41.7 |
|
$ |
66.4 |
|
$ |
(20.4 |
) |
$ |
14.1 |
|
$ |
(58.1 |
) |
$ |
43.7 |
|
|
$ |
58.7 |
|
$ |
49.4 |
|
$ |
(20.4 |
) |
$ |
14.1 |
|
$ |
(58.1 |
) |
$ |
43.7 |
|
Operating margin |
|
10.3 |
% |
|
11.7 |
% |
|
(4.0 |
)% |
|
11.2 |
% |
|
— |
|
|
2.7 |
% |
|
|
8.1 |
% |
|
20.3 |
% |
|
(4.0 |
)% |
|
11.2 |
% |
|
— |
|
|
2.7 |
% |
|
As Reported |
|
|
As Recast |
|
||||||||||||||||||||||||||||||||
|
BSI BioSpin |
|
BSI CALID |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
|
BSI BIOS |
|
BSI BMID |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
||||||||||||
Three months ended September 30, 2025 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
208.7 |
|
$ |
312.7 |
|
$ |
266.5 |
|
$ |
72.6 |
|
|
— |
|
$ |
860.5 |
|
|
$ |
391.2 |
|
$ |
130.2 |
|
$ |
266.5 |
|
$ |
72.6 |
|
|
— |
|
$ |
860.5 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
1.2 |
|
|
— |
|
|
1.2 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
1.2 |
|
|
— |
|
|
1.2 |
|
Total segment revenue |
$ |
208.7 |
|
$ |
312.7 |
|
$ |
266.5 |
|
$ |
73.8 |
|
|
— |
|
$ |
861.7 |
|
|
$ |
391.2 |
|
$ |
130.2 |
|
$ |
266.5 |
|
$ |
73.8 |
|
|
— |
|
$ |
861.7 |
|
Gross profit |
$ |
90.4 |
|
$ |
159.0 |
|
$ |
118.4 |
|
$ |
11.6 |
|
|
— |
|
$ |
379.4 |
|
|
$ |
172.9 |
|
$ |
76.5 |
|
$ |
118.4 |
|
$ |
11.6 |
|
|
— |
|
$ |
379.4 |
|
Gross profit margin |
|
43.3 |
% |
|
50.8 |
% |
|
44.4 |
% |
|
15.7 |
% |
|
— |
|
|
44.1 |
% |
|
|
44.2 |
% |
|
58.8 |
% |
|
44.4 |
% |
|
15.7 |
% |
|
— |
|
|
44.1 |
% |
Operating income |
$ |
8.5 |
|
$ |
47.4 |
|
$ |
(72.2 |
) |
$ |
4.6 |
|
$ |
(40.1 |
) |
$ |
(51.8 |
) |
|
$ |
24.6 |
|
$ |
31.3 |
|
$ |
(72.2 |
) |
$ |
4.6 |
|
$ |
(40.1 |
) |
$ |
(51.8 |
) |
Operating margin |
|
4.1 |
% |
|
15.2 |
% |
|
(27.1 |
)% |
|
6.2 |
% |
|
— |
|
|
(6.0 |
)% |
|
|
6.3 |
% |
|
24.0 |
% |
|
(27.1 |
)% |
|
6.2 |
% |
|
— |
|
|
(6.0 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Nine months ended September 30, 2025 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
611.8 |
|
$ |
878.6 |
|
$ |
775.2 |
|
$ |
193.7 |
|
|
— |
|
$ |
2,459.3 |
|
|
$ |
1,117.1 |
|
$ |
373.3 |
|
$ |
775.2 |
|
$ |
193.7 |
|
|
— |
|
$ |
2,459.3 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
5.7 |
|
|
— |
|
|
5.7 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
5.7 |
|
|
— |
|
|
5.7 |
|
Total segment revenue |
$ |
611.8 |
|
$ |
878.6 |
|
$ |
775.2 |
|
$ |
199.4 |
|
|
— |
|
$ |
2,465.0 |
|
|
$ |
1,117.1 |
|
$ |
373.3 |
|
$ |
775.2 |
|
$ |
199.4 |
|
|
— |
|
$ |
2,465.0 |
|
Gross profit |
$ |
267.5 |
|
$ |
457.6 |
|
$ |
365.8 |
|
$ |
37.6 |
|
|
— |
|
$ |
1,128.5 |
|
|
$ |
509.4 |
|
$ |
215.7 |
|
$ |
365.8 |
|
$ |
37.6 |
|
|
— |
|
$ |
1,128.5 |
|
Gross profit margin |
|
43.7 |
% |
|
52.1 |
% |
|
47.2 |
% |
|
18.9 |
% |
|
— |
|
|
45.9 |
% |
|
|
45.6 |
% |
|
57.8 |
% |
|
47.2 |
% |
|
18.9 |
% |
|
— |
|
|
45.9 |
% |
Operating income |
$ |
50.2 |
|
$ |
113.8 |
|
$ |
(92.6 |
) |
$ |
18.7 |
|
$ |
(98.2 |
) |
$ |
(8.1 |
) |
|
$ |
83.3 |
|
$ |
80.7 |
|
$ |
(92.6 |
) |
$ |
18.7 |
|
$ |
(98.2 |
) |
$ |
(8.1 |
) |
Operating margin |
|
8.2 |
% |
|
13.0 |
% |
|
(11.9 |
)% |
|
9.4 |
% |
|
— |
|
|
(0.3 |
)% |
|
|
7.5 |
% |
|
21.6 |
% |
|
(11.9 |
)% |
|
9.4 |
% |
|
— |
|
|
(0.3 |
)% |
|
As Reported |
|
|
As Recast |
|
||||||||||||||||||||||||||||||||
|
BSI BioSpin |
|
BSI CALID |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
|
BSI BIOS |
|
BSI BMID |
|
BSI NANO |
|
BEST |
|
Corporate |
|
Total |
|
||||||||||||
Fiscal year ended December 31, 2025 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
878.8 |
|
$ |
1,210.2 |
|
$ |
1,084.3 |
|
$ |
263.2 |
|
|
— |
|
$ |
3,436.5 |
|
|
$ |
1,580.1 |
|
$ |
508.9 |
|
$ |
1,084.3 |
|
$ |
263.2 |
|
|
— |
|
$ |
3,436.5 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
7.7 |
|
|
— |
|
|
7.7 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
7.7 |
|
|
— |
|
|
7.7 |
|
Total segment revenue |
$ |
878.8 |
|
$ |
1,210.2 |
|
$ |
1,084.3 |
|
$ |
270.9 |
|
|
— |
|
$ |
3,444.2 |
|
|
$ |
1,580.1 |
|
$ |
508.9 |
|
$ |
1,084.3 |
|
$ |
270.9 |
|
|
— |
|
$ |
3,444.2 |
|
Gross profit |
$ |
389.1 |
|
$ |
625.6 |
|
$ |
516.3 |
|
$ |
46.7 |
|
|
— |
|
$ |
1,577.7 |
|
|
$ |
729.1 |
|
$ |
285.6 |
|
$ |
516.3 |
|
$ |
46.7 |
|
|
— |
|
$ |
1,577.7 |
|
Gross profit margin |
|
44.3 |
% |
|
51.7 |
% |
|
47.6 |
% |
|
17.2 |
% |
|
— |
|
|
45.9 |
% |
|
|
46.1 |
% |
|
56.1 |
% |
|
47.6 |
% |
|
17.2 |
% |
|
— |
|
|
45.9 |
% |
Operating income |
$ |
104.3 |
|
$ |
153.3 |
|
$ |
(71.8 |
) |
$ |
19.4 |
|
$ |
(137.0 |
) |
$ |
68.2 |
|
|
$ |
168.8 |
|
$ |
88.8 |
|
$ |
(71.8 |
) |
$ |
19.4 |
|
$ |
(137.0 |
) |
$ |
68.2 |
|
Operating margin |
|
11.9 |
% |
|
12.7 |
% |
|
(6.6 |
%) |
|
7.2 |
% |
|
— |
|
|
2.0 |
% |
|
|
10.7 |
% |
|
17.4 |
% |
|
(6.6 |
%) |
|
7.2 |
% |
|
— |
|
|
2.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Fiscal year ended December 31, 2024 |
|
||||||||||||||||||||||||||||||||||||
Revenue from external customers |
$ |
905.7 |
|
$ |
1,093.5 |
|
$ |
1,098.3 |
|
$ |
268.9 |
|
|
— |
|
$ |
3,366.4 |
|
|
$ |
1,577.5 |
|
$ |
421.7 |
|
$ |
1,098.3 |
|
$ |
268.9 |
|
|
— |
|
$ |
3,366.4 |
|
Intersegment revenue |
|
— |
|
|
— |
|
|
— |
|
|
14.1 |
|
|
— |
|
|
14.1 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
14.1 |
|
|
— |
|
|
14.1 |
|
Total segment revenue |
$ |
905.7 |
|
$ |
1,093.5 |
|
$ |
1,098.3 |
|
$ |
283.0 |
|
|
— |
|
$ |
3,380.5 |
|
|
$ |
1,577.5 |
|
$ |
421.7 |
|
$ |
1,098.3 |
|
$ |
283.0 |
|
|
— |
|
$ |
3,380.5 |
|
Gross profit |
$ |
453.9 |
|
$ |
593.9 |
|
$ |
540.4 |
|
$ |
61.3 |
|
|
— |
|
$ |
1,649.5 |
|
|
$ |
803.2 |
|
$ |
244.6 |
|
$ |
540.4 |
|
$ |
61.3 |
|
|
— |
|
$ |
1,649.5 |
|
Gross profit margin |
|
50.1 |
% |
|
54.3 |
% |
|
49.2 |
% |
|
21.7 |
% |
|
— |
|
|
49.0 |
% |
|
|
50.9 |
% |
|
58.0 |
% |
|
49.2 |
% |
|
21.7 |
% |
|
— |
|
|
49.0 |
% |
Operating income |
$ |
157.8 |
|
$ |
180.0 |
|
$ |
2.3 |
|
$ |
34.9 |
|
$ |
(121.9 |
) |
$ |
253.1 |
|
|
$ |
235.9 |
|
$ |
101.9 |
|
$ |
2.3 |
|
$ |
34.9 |
|
$ |
(121.9 |
) |
$ |
253.1 |
|
Operating margin |
|
17.4 |
% |
|
16.5 |
% |
|
0.2 |
% |
|
12.3 |
% |
|
— |
|
|
7.5 |
% |
|
|
15.0 |
% |
|
24.2 |
% |
|
0.2 |
% |
|
12.3 |
% |
|
— |
|
|
7.5 |
% |